These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11098546)

  • 1. [Significance of matrix metalloproteinases in cardiovascular diseases].
    Lamparter S; Maisch B
    Z Kardiol; 2000 Oct; 89(10):949-57. PubMed ID: 11098546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases in cardiovascular disease.
    Liu P; Sun M; Sader S
    Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):25B-30B. PubMed ID: 16498509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices.
    Li YY; Feng Y; McTiernan CF; Pei W; Moravec CS; Wang P; Rosenblum W; Kormos RL; Feldman AM
    Circulation; 2001 Sep; 104(10):1147-52. PubMed ID: 11535571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction.
    Cleutjens JP; Creemers EE
    J Card Fail; 2002 Dec; 8(6 Suppl):S344-8. PubMed ID: 12555143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How could analyzing the activity of two matrix metalloproteinases unveil the cause of sudden cardiac death.
    Sosa I; Grubesic A
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):712-714. PubMed ID: 27271976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlling myocardial matrix remodeling: implications for heart failure.
    Rao VU; Spinale FG
    Cardiol Rev; 1999; 7(3):136-43. PubMed ID: 10423664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG; Coker ML; Bond BR; Zellner JL
    Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases: their biological functions and clinical implications.
    Hijova E
    Bratisl Lek Listy; 2005; 106(3):127-32. PubMed ID: 16026148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Extracellular matrix and atherosclerosis].
    Wang KY; Tanimoto A; Sasaguri Y
    J UOEH; 2010 Jun; 32(2):195-203. PubMed ID: 20549907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular remodeling in heart failure: the role of myocardial collagen.
    Janicki JS; Brower GL; Henegar JR; Wang L
    Adv Exp Med Biol; 1995; 382():239-45. PubMed ID: 8540401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.
    Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T
    Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
    Li YY; McTiernan CF; Feldman AM
    Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
    Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMPs--role in cardiovascular development and disease.
    Brauer PR
    Front Biosci; 2006 Jan; 11():447-78. PubMed ID: 16146744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of matrix metalloproteinases in the development of vascular complications of diabetes mellitus--clinical implications].
    Rogowicz A; Zozulińska D; Wierusz-Wysocka B
    Pol Arch Med Wewn; 2007 Mar; 117(3):43-8. PubMed ID: 17718052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG
    Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients.
    Batlle M; Pérez-Villa F; García-Pras E; Lázaro A; Orús J; Roqué M; Roig E
    Transplant Proc; 2007 Sep; 39(7):2344-6. PubMed ID: 17889183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMP induction and inhibition in myocardial infarction.
    Lindsey ML
    Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.